On the other hand, JMJD3, when induced by all-trans retinoid acid (ATRA) signaling, is also known to have an oncorepressive role as it acts on targets such as C/EBPβ and RIPK3 (a key suppressor of AML malignancy) that allow the myeloid differentiation, cell cycle arrest, and cell death of AML cells [71]. Here, KDM6B is linked to acute myeloid leukemia.